DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

流感病毒疫苗小分子双佐剂体系的研制

• 批准号: 10935796
• 负责人: JENNIFER LAPEK
• 金额: $ 247.18万
• 依托单位: SCRIPPS INSTITUTION OF OCEANOGRAPHY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2028-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10935796
• 关键词: Adjuvant; Agonist; Animal Model; Animals; Chronic Disease; Clinical Trials; Communicable Diseases; Contractor; Development; Drug Kinetics; Elderly; Fluzone; Formulation; Frequencies; Human; Immune; Immunization; Individual; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B Virus; Modeling; Mus; Patients; Prevention; Route; Structure-Activity Relationship; Support Contracts; System; TLR4 gene; TLR7 gene; Toxicology; Vaccine Adjuvant; Vaccines; aged; cross immunity; dosage; efficacy study; immunogenicity; improved; influenza virus strain; influenza virus vaccine; influenzavirus; manufacture; novel vaccines; protective efficacy; safety study; seasonal influenza; small molecule

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.

“预防胜于治愈”，是感染疾病的疫苗背后的动机。当前的影响力疫苗需要帮助，因为它们仅在短时间内有效，尤其是在基本人和慢性疾病患者中。此外，必须每年准备新的疫苗，以防止新的影响力病毒。这是对开发新的免疫促进调节剂的需求，以改善现有的影响力疫苗。我们的合同支持开发可调节的新疫苗FOS47，该疫苗可改善动物模型中的疫苗耐用性和交叉保护。疫苗可调节的FOS47的保护效率将在影响力病毒挑战模型中进行评估，以确定免疫抑制的最佳剂量，路线和频率。可调节的疫苗将大规模制备以开始人类临床试验。